International journal of clinical oncology · 2026
Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasone.
СтатьяСистематический обзорСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aoyama Takeshi, Iihara Hirotoshi, Abe Masakazu, Wada Makoto, Iino Keiko, Akechi Tatsuo, Imamura Chiyo K, Okuyama Ayako, Ozawa Keiko, Kim Yong-Il, Sasaki Hidenori, Satomi Eriko, Takeda Masayuki, Tanaka Ryuhei, Nakajima Takako Eguchi, Nakamura Naoki, Nishimura Junichi, Noda Mayumi, Hayashi Kazumi, Higashi Takahiro, Boku Narikazu, Matsumoto Koji, Matsumoto Yoko, Okita Kenji, Yamamoto Nobuyuki, Aogi Kenjiro
Аннотация
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) significantly impact quality of life of patients with cancer. Although antiemetic guidelines exist for low-emetic chemotherapy (LEC), recommendations vary across international guidelines and direct evidence comparing 5-HT3 receptor antagonists (5-HT3 RAs) with dexamethasone monotherapy is lacking.
METHODS: We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for randomized controlled trials, nonrandomized comparative studies, and observational studies directly comparing 5-HT3 RA with dexamethasone monotherapy in adult patients with LE, using PubMed, the Cochrane Library, CINAHL, and Ichushi-Web from January 1990 to December 2020.
RESULTS: A systematic search identified 427 articles (87 from PubMed, 337 from the Cochrane Library, and three from Ichushi-Web), with three additional records identified through other sources. After the first screening of 430 articles, 425 records were excluded, and five records were used for full-text assessment. Following the second screening, five full-text articles were excluded for not meeting the inclusion criteria.
CONCLUSIONS: This systematic review identified no direct comparative evidence. Future efforts to strengthen the evidence base should include not only prospective comparative trials where feasible but also observational studies, real-world data analyses, and other complementary approaches that better reflect routine clinical practice.
METHODS: We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for randomized controlled trials, nonrandomized comparative studies, and observational studies directly comparing 5-HT3 RA with dexamethasone monotherapy in adult patients with LE, using PubMed, the Cochrane Library, CINAHL, and Ichushi-Web from January 1990 to December 2020.
RESULTS: A systematic search identified 427 articles (87 from PubMed, 337 from the Cochrane Library, and three from Ichushi-Web), with three additional records identified through other sources. After the first screening of 430 articles, 425 records were excluded, and five records were used for full-text assessment. Following the second screening, five full-text articles were excluded for not meeting the inclusion criteria.
CONCLUSIONS: This systematic review identified no direct comparative evidence. Future efforts to strengthen the evidence base should include not only prospective comparative trials where feasible but also observational studies, real-world data analyses, and other complementary approaches that better reflect routine clinical practice.